Aqualung Publications

Insight. Impact. Innovation.
Peer-reviewed research on eNAMPT and the ALT-100 antibody

Peer-reviewed publications on eNAMPT and the ALT-100 antibody, grouped by program. Links go to PubMed or the publisher.

Clinical studies of ALT-100

  1. Safety, Tolerability and Pharmacokinetics of the eNAMPT-Neutralizing ALT-100 mAb in Healthy VolunteersMiele S, et al., 2024
  2. Early Safety/Therapeutic Results of ALT-100 eNAMPT mAb Impact in the PUERTA Phase 2A ARDS TrialGarcia JGN, et al. Am J Respir Crit Care Med, 2026

Progressive pulmonary fibrosis

  1. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary FibrosisCasanova NG, et al. Am J Respir Cell Mol Biol, 2025

Acute respiratory distress syndrome (ARDS)

  1. Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibodyQuijada H, et al. Eur Respir J, 2021
  2. eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signalingBermudez T, et al. Sci Rep, 2022
  3. eNAMPT Neutralization Preserves Lung Fluid Balance and Reduces Acute Renal Injury in Porcine Sepsis/VILI-Induced Inflammatory Lung InjuryFront Physiol, 2022

Bone-metastatic prostate cancer and cancer-induced bone pain

  1. Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic targetSun BL, et al. EBioMedicine, 2020
  2. A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer ProgressionSun BL, et al. Pharmaceuticals, 2021
  3. A humanized eNAMPT-neutralizing monoclonal antibody reduces cancer-induced bone pain and osteoclastogenesis in murine breast cancer modelMathur NC, et al. Front Pain Res, 2026

Neonatal RDS, BPD and intra-amniotic inflammation

  1. The eNAMPT/TLR4 inflammatory cascade drives the severity of intra-amniotic inflammation in pregnancy and predicts infant outcomesAhmed M, et al. Front Physiol, 2023
  2. Extracellular Nicotinamide Phosphoribosyltransferase Is a Therapeutic Target in Experimental Necrotizing EnterocolitisHalpern MD, et al. Biomedicines, 2024

Pulmonary hypertension

  1. Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial HypertensionChen J, et al. Circulation, 2017
  2. Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular RemodelingSun X, et al. Am J Respir Cell Mol Biol, 2020
  3. Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAbAhmed M, et al. Pulm Circ, 2021
  4. eNAMPT/TLR4 signaling drives PAH cellular phenotypic switching and lung vascular remodelingAhmed M, et al. Cell Commun Signal, 2025

Inflammatory bowel disease and lupus vasculitis

  1. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitisColombo G, et al. J Mol Med, 2020
  2. NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel diseaseColombo G, et al. Front Med, 2023
  3. eNAMPT/TLR4 inflammatory cascade activation is a key contributor to SLE Lung vasculitis and alveolar hemorrhageTurmuukhuu S, et al. J Transl Autoimmun, 2023

Research programs

  1. eNAMPT Is a Novel Damage-associated Molecular Pattern Protein That Contributes to the Severity of Radiation-induced Lung FibrosisGarcia AN, et al. Am J Respir Cell Mol Biol, 2022
  2. Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralizationRadiation-induced lung injury, 2021
  3. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosisSun BL, et al. FASEB J, 2023
  4. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancerTravelli C, et al., 2023
  5. eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetesMakino, et al. Diabetologia, 2024
  6. An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunctionCardiac fibrosis, 2024

ALT-100 is an investigational drug. It has not been approved by the FDA or any other regulatory authority.